Company · codman-shurtleff-aaee347e
Codman & Shurtleff
4 sourcescompanies-2026-11-14-0.1.0
Cite this record
ConductScience Library. Codman & Shurtleff. Companies, record codman-shurtleff-aaee347e. Release companies-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/companies/codman-shurtleff-aaee347e
On this page
Company
The name as ClinicalTrials.gov gives it. A company is a name ClinicalTrials.gov classes as industry, and spellings that differ only in case or spacing are one; no subsidiary is folded into a parent. A trial of two phases counts in both, and recruiting trials count as active.
- Name
- Codman & Shurtleff
- Trials
- 18
- As lead sponsor
- 17
- As collaborator
- 1
- Recruiting
- 0
- Active, recruiting or not
- 0
- Completed
- 15
- Stopped early, withdrawn or suspended
- 3
- Posted results
- 6
- Trials by phase
- Phase 1 3, Phase 2 2, Phase 3 2, Phase 4 2
- Drugs its trials test
- 2
- Comparisons calculated in its trials
- 3
- First trial registered
- 2005-09-20
- Last update
- 2019-10-18
Source ClinicalTrials.gov
Pipeline2
The drugs its trials test, by the trial links the pipelines release's checks show. The phase is the highest phase those trials registered on ClinicalTrials.gov, not a development stage. Highest phase first, then the most trials.
| Drug | Highest phase registered | Trials | As lead sponsor | Recruiting | Targets | Mechanism | In Drugs and targets | Source |
|---|---|---|---|---|---|---|---|---|
| ASPIRIN | Phase 2/3 | 1 | 1 | 0 | PTGS1, PTGS2 | Cyclooxygenase inhibitor | https://conductscience.org/library/drugs/CHEMBL25 | Open Targets |
| CLOPIDOGREL | Phase 2/3 | 1 | 1 | 0 | P2RY12 | Purinergic receptor P2Y12 antagonist | https://conductscience.org/library/drugs/CHEMBL1771 | Open Targets |
Trials18
The trials that name the company as lead sponsor or collaborator, newest registered first. Results posted are as ClinicalTrials.gov gave them on the day of the sponsors capture.
| Trial | Title | Role | Phase | Status | Type | Participants | Start | Results first posted | Drugs | In Trials | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02169492 | Evaluation of the ReVive SE Device for Intra-Arterial Thrombectomy in Acute Ischemic Stroke | Lead sponsor | Completed | Observational | 103 | 2015-01-01 | https://conductscience.org/library/trials/NCT02169492 | ClinicalTrials.gov | |||
| NCT01945827 | Evaluation of DeltaMaxx® Microcoil System in Intracranial Aneurysms | Lead sponsor | Withdrawn | Observational | 0 | 2014-01 | https://conductscience.org/library/trials/NCT01945827 | ClinicalTrials.gov | |||
| NCT01712087 | Long-term Surveillance of the MedStream Programmable Infusion System | Lead sponsor | Terminated | Observational | 2 | 2012-10-01 | https://conductscience.org/library/trials/NCT01712087 | ClinicalTrials.gov | |||
| NCT01503775 | TRUfill®'s Line in Intracranial aNeurysm Embolisation | Lead sponsor | Completed | Observational | 171 | 2011-12-01 | https://conductscience.org/library/trials/NCT01503775 | ClinicalTrials.gov | |||
| NCT01259271 | Selective Nerve Stimulation (SNS) Pilot Study | Lead sponsor | Early phase 1 | Completed | Interventional | 60 | 2010-11-01 | https://conductscience.org/library/trials/NCT01259271 | ClinicalTrials.gov | ||
| NCT00879580 | Enterprise Stent Aneurysm Treatment (ESAT) Study - France | Lead sponsor | Completed | Observational | 133 | 2009-02 | https://conductscience.org/library/trials/NCT00879580 | ClinicalTrials.gov | |||
| NCT00816166 | VISSIT Intracranial Stent Study for Ischemic Therapy | Lead sponsor | Phase 2/3 | Terminated | Interventional | 125 | 2008-10 | 2014-06-16 | ASPIRIN, CLOPIDOGREL | https://conductscience.org/library/trials/NCT00816166 | ClinicalTrials.gov |
| NCT00663299 | COMPLEX Post Market Surveillance Electronic Registry | Lead sponsor | Not applicable | Completed | Interventional | 299 | 2004-06 | https://conductscience.org/library/trials/NCT00663299 | ClinicalTrials.gov | ||
| NCT00486226 | The Registry to Study Safety and Performance of the CORDIS Vascular Reconstruction Device and Delivery System | Lead sponsor | Completed | Observational | 105 | 2007-06-01 | 2014-04-21 | https://conductscience.org/library/trials/NCT00486226 | ClinicalTrials.gov | ||
| NCT00349908 | A Feasibility Study of the Cordis Neurovascular Self Expanding Stent System in Intracranial Arteries | Lead sponsor | Phase 1 | Completed | Interventional | 20 | 2006-09 | 2013-10-11 | https://conductscience.org/library/trials/NCT00349908 | ClinicalTrials.gov |
1 to 10 of 18
See all 18 trialsConditions18
The conditions its trials name, as the trials write them, with case and spacing folded. The most trials first.
| Condition | Trials |
|---|---|
| Intracranial Aneurysm | 3 |
| Aneurysms | 2 |
| Hydrocephalus | 2 |
| Normal Pressure Hydrocephalus | 2 |
| Aneurysm | 1 |
| Atherosclerosis | 1 |
| Chronic Pain | 1 |
| Healthy | 1 |
| Idiopathic Normal Pressure Hydrocephalus | 1 |
| Intracranial Aneurysms | 1 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 conditionsPartners6
The other organizations its trials name, as lead sponsor or collaborator, with the class ClinicalTrials.gov gives each. The most trials shared first. A partner that is a company opens its own record.
| Organization | Class | Trials shared | In Companies | Source |
|---|---|---|---|---|
| American Association of Neurological Surgeons | Other | 1 | ClinicalTrials.gov | |
| Daiichi Pharmaceuticals | Industry | 1 | https://conductscience.org/library/companies/daiichi-pharmaceuticals-d2fbc7e6 | ClinicalTrials.gov |
| Eisai Limited | Industry | 1 | https://conductscience.org/library/companies/eisai-limited-db8abc87 | ClinicalTrials.gov |
| Johnson & Johnson | Industry | 1 | https://conductscience.org/library/companies/johnson-johnson-5f2ec140 | ClinicalTrials.gov |
| Nihon Medi-Physics Co., Ltd. | Industry | 1 | https://conductscience.org/library/companies/nihon-medi-physics-co-ltd-868639f7 | ClinicalTrials.gov |
| Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Other | 1 | ClinicalTrials.gov |
Data dates
The date of each source this release read.
Sources 4
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL
- ClinicalTrials.govNo license stated
- Open TargetsCC0 1.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBLCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this company from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/companies/v1/codman-shurtleff-aaee347e
GET https://conductscience.org/api/companies/v1/codman-shurtleff-aaee347e/pipeline